Does Ozempic actually help with PCOS symptoms?

What did @pcosdiaries.ph actually say?

The creator, who presents as a doctor and PCOS patient, makes three core arguments: GLP-1 receptor agonists like semaglutide (Ozempic) and liraglutide can be appropriate for PCOS when prescribed by an endocrinologist or primary care physician, that these drugs work on insulin resistance and have weight loss as a side effect rather than a primary mechanism, and that lifestyle modification remains "number one treatment" for PCOS above any medication. She also warns that PCOS management is "highly personalized" and that what works for one patient may not work for another.

The transcript is heavily mixed between English and what appears to be Filipino, with some garbled sections that make precise quoting difficult. But the clinical thrust is clear enough to fact-check. She is not selling anything, not naming a dose, and consistently redirects viewers to their own doctors. That framing matters.

Does the science back this up?

Mostly, yes, though the insulin resistance framing deserves some nuance. GLP-1 receptor agonists do show real benefit in PCOS populations, but the mechanism is more complex than the video implies.

A 2023 meta-analysis by Elkind-Hirsch et al. in Fertility and Sterility found that GLP-1 receptor agonists significantly reduced BMI, fasting insulin, and testosterone levels in women with PCOS compared to placebo. A separate 2022 randomized controlled trial by Nylander et al. in Human Reproduction found liraglutide improved menstrual regularity and androgen profiles in PCOS patients independent of weight loss, which complicates the simple "weight loss side effect" story the creator tells.

On insulin resistance specifically: yes, GLP-1 drugs improve insulin sensitivity, but they do so through multiple pathways, including direct pancreatic beta-cell effects, slowed gastric emptying, and central appetite suppression. Framing it purely as an insulin resistance fix undersells the pharmacology.

Her point that lifestyle modification is first-line is supported by every major clinical guideline. The 2023 international evidence-based guideline for PCOS assessment and management, published by Teede et al. in Human Reproduction, lists lifestyle intervention as the foundation of treatment before any pharmacological option.

What did they get wrong (or right)?

She got the hierarchy right. Lifestyle first, medications second, personalized monitoring throughout. That is not a controversial position, it is the clinical consensus.

Where she slides into imprecision: describing weight loss as merely a "side effect" of GLP-1 drugs is technically accurate for the original diabetes indication, but in the PCOS context, weight reduction is often a primary therapeutic goal, not incidental. Framing it as a bonus undersells why doctors are actually prescribing these drugs off-label for PCOS in the first place.

She also does not mention that semaglutide and liraglutide are not approved by any major regulatory agency specifically for PCOS. They are prescribed off-label. That is a material omission for a video aimed at patients who may not understand the difference between approved and off-label use. Off-label prescribing is legal and often evidence-based, but patients deserve to know that distinction.

Her consistent refrain, "if your doctor prescribed it, your doctor assessed you," is reasonable as a general principle but slightly circular. Prescription does not automatically equal appropriate assessment, especially in contexts where telehealth prescribing has outpaced clinical rigor.

What should you actually know?

GLP-1 receptor agonists are not approved by the FDA or Philippine FDA specifically for PCOS. If you are being considered for one, the conversation with your doctor should include why this drug, what outcomes you are targeting, and what monitoring plan is in place.

The evidence base is growing but not large. Most trials on GLP-1s in PCOS have small sample sizes and short follow-up periods. The 2023 Teede guidelines note that while early data is promising, long-term safety data in PCOS populations specifically remains limited.

Lifestyle modification is not a platitude here. Studies consistently show that even a 5 to 10 percent reduction in body weight improves hormonal profiles, menstrual regularity, and fertility outcomes in overweight women with PCOS (Lim et al., 2019, Obesity Reviews). GLP-1 drugs can support that goal, but they do not replace it.

Finally, if you are in the Philippines and considering these medications, cost and supply chain are real barriers. Brand-name semaglutide remains expensive, and compounded versions carry regulatory and quality risks that are not equivalent to approved formulations.

Our overall take

This video is more responsible than most PCOS content on TikTok. The creator does not promise a cure, does not name a dose, and repeatedly sends viewers back to their physicians. The science she references is real, if simplified. The main gaps are the off-label disclosure and the oversimplification of how GLP-1 drugs actually work. For a 39K-view health video, the harm ceiling here is low. But patients deserve the full picture, not just the reassuring parts.